Supplementary materials: Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs

These are peer-reviewed supplementary materials for the article 'Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs' published in the Journal of Comparative Effectiveness Research.Supplemental Table 1: ICD-O-3 codes for identification of NSCLCSupplemental Table 2: Procedure codes used to identify lung cancer-related surgerySupplemental Table 3: Pharmaceutical costs (2021 USD) during the observation period by disease stage at diagnosis and therapy typeSupplemental Table 4: Medical costs (2021 USD) during the observation period by type of surgery each patient receivedSupplemental Table 5: Healthcare resource utilization (HRU) and costs (2021 USD) during the observation period by phase of careAim: To quantify the economic burden of early-stage non-small-cell lung cancer (NSCLC) among patients with and without adjuvant therapy. Methods: All-cause and NSCLC-related healthcare resource utilization and medical costs were assessed among patients with resected stage IB–IIIA NSCLC in the SEER–Medicare database (1 January 2011–31 December 2019), from NSCLC diagnosis to death, end of continuous enrollment, or end of data availability (whichever occurred first). Results: Patients receiving adjuvant therapy had the lowest mean NSCLC-related medical costs (adjuvant [n = 1776]: $3738; neoadjuvant [n = 56]: $5793; both [n = 47]: $4818; surgery alone [n = 3478]: $4892, per-person-per-month), driven by lower NSCLC-related hospitalization rates. Conclusion: Post-surgical management of early-stage NSCLC was associated with high economic burden. Adjuvant therapy was associated with numerically lower medical costs over surgical resection alone.

本数据集为发表于《比较有效性研究杂志》之文章《早期非小细胞肺癌的经济负担：对医疗资源利用和医疗费用的评估》的同行评审补充材料。补充表1：用于识别NSCLC的ICD-O-3编码；补充表2：用于识别与肺癌相关手术的手术编码；补充表3：观察期内按疾病诊断阶段和治疗类型划分的药品费用（2021年美元）；补充表4：观察期内按每位患者接受的手术类型划分的医疗费用（2021年美元）；补充表5：观察期内按护理阶段划分的医疗资源利用（HRU）和费用（2021年美元）。研究目的：量化有和没有辅助治疗的患者早期非小细胞肺癌（NSCLC）的经济负担。研究方法：在SEER-Medicare数据库中（2011年1月1日至2019年12月31日），对切除IIB-III期NSCLC的患者进行了全因和NSCLC相关医疗资源利用和医疗费用的评估，从NSCLC诊断至死亡、连续注册结束或数据可用性结束（以先发生者为准）。研究结果：接受辅助治疗的患者具有最低的平均NSCLC相关医疗费用（辅助治疗[n = 1776]：3738美元；新辅助治疗[n = 56]：5793美元；两者都有[n = 47]：4818美元；单独手术[n = 3478]：4892美元，每人每月），这得益于较低的NSCLC相关住院率。研究结论：早期NSCLC的术后管理与较高的经济负担相关。辅助治疗与单纯手术相比，在医疗费用上具有数量上的降低。